Taiwan adopts new approach to biotechnology-related invention applications

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Taiwan adopts new approach to biotechnology-related invention applications

Sponsored by

saint-island-400px.png
plant-tissue-culture-facility-2223464.jpg

Fiona Yin of Saint Island International Patent & Law Offices explains the ramifications of an announcement by the TIPO with regard to the implementation of WIPO Standard ST.26

In applying for biotechnology-related inventions, apart from submitting to the Taiwan Intellectual Property Office a copy of the specification with claims and necessary drawings, inter alia, the applicant should also pay attention to:

  • Whether the claimed invention involves a sequence of nucleotides or amino acids and hence a sequence listing needs to be filed; and

  • Whether it is necessary to make a domestic deposit of the involved biomaterials to meet the enabling requirement.

An announcement in July 2022 by TIPO relating to the above requirements is summarised as follows.

WIPO Standard ST.26 WIPO Standard ST.25 now only applies to any and all biotechnology-related invention applications filed before July 1 2022; i.e., it is only necessary to submit TIPO sequence listings in electronic TXT format for such cases. Following the adoption of a new standard by WIPO, starting from August 1 2022, sequence listings in XML files prepared in accordance with WIPO Standard ST.26, rather than the ST.25 standard, must be submitted with the relevant biotechnology-related invention applications in Taiwan.

Although nucleotide or amino acid sequences associated with biotechnogy-related inventions are mostly referred to in the Specifications, in order to facilitate exchange of sequence information and the necessary prior art searching and analysis, the applicant is required to prepare WIPO Standard sequence listings in XML files separately and attach the same to the electronic copy of the specification as part of the disclosure of the invention.

When a foreign applicant obtains the filing date of a patent application in the original language (for example, In English) and requests a belated submission of the Chinese version specification, Chinese version sequence listings prepared in accordance with WIPO Standard ST.26 need to be filed as well.

With regard to divisional applications, the applicant may choose to file sequence listings prepared in accordance with WIPO Standard ST.26 or sequence listings in TXT files, as is its parent application.

Viability statement

As Taiwan is not a member country of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the effect of a deposit made in an international depository under the treaty is generally not recognised in Taiwan. Hence, although certain biomaterials have been deposited in an international depository to meet the enabling requirement, the applicant is still required to make a corresponding deposit in a domestic depository designated by TIPO.

A domestic deposit can be exempted only when the international deposit was made in the UK, Japan, or South Korea, with which Taiwan has signed respective reciprocity agreements with regard to the depositing of biomaterials. In this respect, the certificates of deposit issued from the depository in the above three countries still need to be filed within four months from the filing date or 16 months from the earliest priority date claimed, whichever is applicable.

Furthermore, according to the announcement, a statement of viability must be indicated on the certificate of deposit. If a certificate of deposit does not contain a viability statement, or contains an unclear statement, the applicant shall be notified to submit a certificate of viability within the statutory period mentioned above. Otherwise, the biomaterials shall be deemed not deposited in the first place.

more from across site and SHARED ros bottom lb

More from across our site

Moore & Van Allen hires former Teva counsel Larry Rickles to help expand the firm’s life sciences capabilities
Canadian law firms should avoid ‘tunnel vision’ as exclusive survey reveals client dissatisfaction with risk management advice and value-added services
In major recent developments, the CoA ruled on director liability for patent infringement, and Nokia targeted Paramount at the UPC and in Germany
Niri Shan, the newly appointed head of IP for UK, Ireland and the Middle East, explains why the firm’s international setup has brought UPC success, and addresses German partner departures
Vlad Stanese joins our ‘Five minutes with’ series to discuss potentially precedent-setting trademark and copyright cases and his love for aviation
Heath Hoglund, president of Via LA, discusses how it sets royalty rates and its plans to build on growth in China
Stobbs stands accused of interfering with the administration of justice after Brandsmiths’ client was subjected to an interim injunction for unjustified threats
The firm, known for its prosecution expertise, discusses its plans following the appointment of a UK-based patent litigation head and two new partners
Ed White at Clarivate provides an exclusive insight into the innovation power clusters reshaping Europe and the Middle East’s IP landscape, and why quality is the new currency of invention
In the first in a new podcast series celebrating the tenth anniversary of IP Inclusive, we look back at the network’s origins and discuss its mission
Gift this article